Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase IIa Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc. announced 12-week interim data from the 320 mg dose group of INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase IIa clinical trial of bexotegrast in patients with idiopathic pulmonary fibrosis.